Chronic phase of ETV6-ABL1 positive CML responds to imatinib

Genes Chromosomes Cancer. 2008 Oct;47(10):919-21. doi: 10.1002/gcc.20593.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Blast Crisis / drug therapy*
  • Female
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imatinib Mesylate
  • In Situ Hybridization, Fluorescence
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Oncogene Proteins, Fusion / genetics*
  • Piperazines / therapeutic use*
  • Polymerase Chain Reaction
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics*
  • Pyrimidines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • TEL-ABL fusion protein, human
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl